Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study

Figures

• 

  Figure 1.. Cumulative incidence of VTE, according to ALK rearrangement status. Outcome events counted from 6 months prior to study index to 5 years post-index. Index date defined as date of NSCLC diagnosis. Death considered as a competing risk. ALK, anaplastic lymphoma kinase; VTE, venous thromboembolism.

• 

  Figure 2.. Cumulative incidence of ATE, according to ALK rearrangement status. Outcome events counted from 6 months prior study index to 5 years post-index. Index date defined as date of NSCLC diagnosis. Death considered as a competing risk. ALK, anaplastic lymphoma kinase; ATE, arterial thromboembolism.